Tirzepatide vs Liraglutide: Research Comparison (UK 2026)

At a glance

Property	Tirzepatide	Liraglutide
Receptor profile	Dual GIP / GLP-1	GLP-1 monoagonist
Developer	Eli Lilly	Novo Nordisk
UK regulatory status	MHRA-licensed (Mounjaro — T2D; obesity indications expanding)	MHRA-licensed (Saxenda — chronic weight management)
Mean weight reduction	≈22% at 72 weeks (SURMOUNT-1, 15 mg)	≈8% at 56 weeks (SCALE Obesity, 3 mg)
Dosing frequency	Once weekly SC injection	Once daily SC injection
Half-life	≈5 days	≈13 hours
Glycaemic control	Robust HbA1c reduction (SURPASS programme)	Moderate HbA1c reduction; licensed for T2D as Victoza
Cardiovascular outcome data	SURMOUNT-MMO ongoing	LEADER trial: 13% MACE reduction (T2D population)
Notable side-effect signal	GI (nausea, diarrhoea, constipation)	GI (nausea predominant at initiation); injection-site reactions

Receptor pharmacology

Liraglutide was the first long-acting GLP-1 receptor agonist to demonstrate clinically meaningful weight reduction in people without diabetes, establishing proof-of-concept for the incretin class in obesity pharmacotherapy. Its mechanism centres entirely on GLP-1 receptor activation: slowing gastric emptying, suppressing glucagon secretion, and centrally reducing appetite via hypothalamic GLP-1R signalling. The requirement for once-daily dosing reflects its 13-hour half-life, which is achieved through a fatty-acid chain enabling reversible albumin binding.

Tirzepatide represents a subsequent generation of incretin pharmacology. Its 39-amino-acid backbone activates both the GIP receptor and the GLP-1 receptor simultaneously. GIP co-agonism appears to potentiate GLP-1-mediated satiety signalling while also acting on adipocytes to modulate lipid metabolism — an effect absent from liraglutide. This additional receptor engagement, combined with a five-day half-life permitting once-weekly dosing, mechanistically underpins the substantially larger weight reduction observed in clinical trials.

From a structural pharmacology perspective, the comparison illustrates how incremental receptor diversification has translated into step-changes in clinical outcome. Liraglutide is the established first-generation benchmark; tirzepatide is the current standard of care for magnitude of weight reduction in the MHRA-licensed class.

Clinical evidence base

The SCALE programme (Saxenda) remains the foundational obesity dataset for liraglutide. SCALE Obesity and Prediabetes (2015, New England Journal of Medicine; n = 3,731) reported a mean placebo-subtracted weight loss of approximately 5.4% at 56 weeks with liraglutide 3 mg, translating to roughly 8% total body weight reduction from baseline. Responder analyses showed approximately 63% of participants achieving ≥5% weight loss versus 27% on placebo — a clinically relevant threshold but modest by contemporary incretin standards.

SURMOUNT-1 (Jastreboff et al., NEJM 2022; n = 2,539) assessed tirzepatide in adults with obesity or overweight plus at least one comorbidity, without diabetes. The 15 mg arm achieved a mean weight reduction of 22.5% at 72 weeks, with 91% of participants reaching ≥5% loss. No direct head-to-head randomised controlled trial of tirzepatide versus liraglutide has been published to date; indirect comparison relies on cross-trial analysis with the caveats of differing population demographics and trial durations. SURMOUNT-4 (2023) demonstrated that weight regain follows tirzepatide discontinuation, a finding paralleled in liraglutide-discontinuation studies from the SCALE programme.

Safety signals

Both compounds share the GLP-1-class gastrointestinal adverse event profile: nausea, vomiting, diarrhoea, and constipation are most common during dose escalation and typically attenuate over six to twelve weeks. Liraglutide at 3 mg carries a boxed warning for thyroid C-cell tumours (rodent carcinogenicity data), which is carried across the GLP-1 class including tirzepatide. Liraglutide has a notable cardiovascular safety advantage over older agents — the LEADER trial (2016) demonstrated a 13% reduction in major adverse cardiovascular events versus placebo in a high-risk type 2 diabetes population — though this benefit was assessed at the 1.8 mg diabetic dose rather than the 3 mg obesity dose. Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing as of 2026.

Injection-site reactions are marginally more frequently reported with liraglutide, likely reflecting the daily injection schedule. Both molecules are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Which to prioritise for research

For researchers examining the evolution of incretin-based obesity pharmacotherapy, the tirzepatide–liraglutide comparison provides the clearest illustration of generational progress: approximately 22% versus 8% mean weight reduction from compounds within the same regulatory category and both licensed by the MHRA. Liraglutide remains valuable in the literature for its cardiovascular outcomes data, its long post-marketing safety record (Victoza approved 2009 in the UK), and as the historical baseline from which subsequent GLP-1 agents are benchmarked. Tirzepatide is the appropriate comparator for contemporary clinical translation studies. Researchers interested in mechanism rather than magnitude — particularly the incremental contribution of GIP receptor co-agonism — will find the liraglutide baseline indispensable.